{"id":"W4399318772","doi":"10.1200/jco.23.02736","title":"Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"ca_institutions":"North York General Hospital","funders":"Cilag; Genentech; Sirtex Medical; Daiichi Sankyo Europe; Servier; Eli Lilly and Company; Ono Pharmaceutical; Eisai; Chugai Pharmaceutical; Seagen; Daiichi Sankyo Company; BeiGene; Halozyme; Mirati Therapeutics; Taiho Pharmaceutical; Array BioPharma; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Les Laboratories Pierre Fabre; PharmaMar; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Colorectal cancer; Lenvatinib; Oncology; Internal medicine; Open label; Randomized controlled trial; Cancer; Immunotherapy; Thyroid cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005681963,0.0002083348,0.005035093,0.0002895565,0.00007399489,0.00002398127,0.000452832,0.0001730259,0.0002509901],"category_scores_gemma":[0.002495,0.0001142894,0.001704372,0.0008420236,0.0005448619,0.0001034958,0.00008564073,0.0005328043,2.741822e-7],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005132034,"about_ca_system_score_gemma":0.005666661,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004395726,"about_ca_topic_score_gemma":0.002432399,"domain_scores_codex":[0.9941066,0.001116072,0.003749096,0.0002664241,0.0005340234,0.0002277776],"domain_scores_gemma":[0.9893932,0.006651673,0.002612293,0.0002607792,0.0009450411,0.0001370609],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8686724,0.002211771,0.0007474287,0.0001921846,0.03196254,0.00009386642,0.001775674,0.00006922037,0.000265685,0.00002821074,0.0009577854,0.09302319],"study_design_scores_gemma":[0.8390634,0.1008358,0.001373465,0.0003876988,0.04716787,0.00003105067,0.001957689,0.001462516,0.0005111289,0.00001897633,0.007072499,0.000117942],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843343,0.009293864,0.0001203556,0.001335598,0.001628332,0.002745619,0.0002129528,0.000007023627,0.0003219939],"genre_scores_gemma":[0.9967122,0.002130624,0.0004765436,0.0001409006,0.0002051225,0.00009981297,0.00001272156,0.000021183,0.0002008668],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09862401,"threshold_uncertainty_score":0.9999703,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1967053973625952,"score_gpt":0.5371934962452657,"score_spread":0.3404880988826705,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}